Osteopore (ASX:OSX) Secures Market Access and Supply Chain for Thailand Orthopaedic Bone Reconstruction Market

Sonal Goyal

30 September 2026 06:10 PM AEST

Osteopore (ASX:OSX) Secures Market Access and Supply Chain for Thailand Orthopaedic Bone Reconstruction Market

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Osteopore Limited (ASX:OSX), an Australian-Singaporean regenerative medicine company and global leader in 3D-printed bioresorbable implants, announced on 9 September 2026 that it has secured market access in Thailand for its full range of orthopaedic products. The company has also established its Supply chain and logistics network into Thailand through a Partnership with DCH Auriga (Auriga), an Asia-based integrated market management provider specialising in healthcare. As part of the arrangement, Auriga will act as Osteopore's market authorisation holder and will Import and supply the company's regenerative devices to hospitals and clinics across Thailand.

About Osteopore

Osteopore Limited (ASX:OSX) is a regenerative medicine company specialising in the development and commercialisation of 3D-printed biomimetic and bioresorbable implants for bone reconstruction. The company's flagship product addresses medial opening wedge high tibial osteotomy procedures, and its broader orthopaedic product range includes scaffolds for bone defect repair arising from trauma, tumour resection, and degenerative disease. Osteopore is led by CEO Dr Yujing Lim and Executive Chairman Mark Leong and is headquartered in Singapore, with an ASX listing.

Thailand Market Access — Announced 9 September 2026

Osteopore secured market access in Thailand for its full range of orthopaedic products through Auriga, which will serve as the market authorisation holder, importer, and distributor into Thai hospitals and clinics. The Thailand orthopaedic devices market was valued at approximately USD 749 million in 2025 and is projected to reach approximately USD 1.5 billion by 2033, reflecting a compound annual growth rate of 9.2% — one of the fastest growth rates in the Asia-Pacific region.

Bone-repair orthobiologics and bone graft substitutes — the segment addressed by Osteopore's scaffolds — typically represent approximately 8–10% of the orthopaedic devices market by value. On that basis, the company estimates the total addressable segment in Thailand at approximately USD 60–80 million annually. Demand is supported by expanding access to reconstructive procedures under Thailand's universal healthcare coverage, a rising orthopaedic disease burden, and high road-trauma rates generating sustained demand for bone defect reconstruction materials.

The next step for Osteopore is to proceed with product listing in target public and private hospitals in Bangkok. The company described Thailand as one of its key ASEAN markets following its evaluation of regional opportunities. CEO Dr Yujing Lim noted that the team has had opportunities to present the regenerative devices at regional meetings and conferences and is looking forward to formal commercial engagements.

Industry Context

The Asia-Pacific orthopaedic devices market has been one of the fastest-growing in the world, driven by population ageing, rising surgical volumes, increasing healthcare access, and high rates of road trauma in developing markets. Thailand's universal healthcare coverage system has been a driver of surgical access for reconstructive procedures. The 3D-printed bioresorbable scaffold market is a developing segment within bone graft substitutes, offering a synthetic alternative to autograft and allograft bone that is fully resorbed by the body and replaced by new bone over time. Osteopore's biomimetic design aims to replicate the porous architecture of natural bone to facilitate cell ingrowth and vascularisation.

Risks and Uncertainties

Market access approval in Thailand marks the entry point for commercial activity, not immediate revenue. The speed of hospital product listing, surgeon uptake, and reimbursement pathways in the Thai market will determine the Revenue contribution from this expansion. Auriga's performance as a distribution partner will be an important variable. Competition from established international orthopaedic device manufacturers in the Thai market is also a relevant factor. Currency risk (AUD/SGD/USD/THB) exists across Osteopore's operational footprint.

FAQs

Q: What is Osteopore's product and where will it be sold in Thailand?

A: Osteopore makes 3D-printed bioresorbable bone reconstruction scaffolds. In Thailand, it will target public and private hospitals in Bangkok through its distribution partner Auriga.

Q: What is the size of Thailand's orthopaedic devices market?

A: The Thai orthopaedic devices market was valued at approximately USD 749 million in 2025 and is projected to reach USD 1.5 billion by 2033 at a 9.2% CAGR.

Q: What is Osteopore's addressable segment in Thailand?

A: Bone-repair orthobiologics typically represent 8–10% of the orthopaedic market by value, implying an estimated addressable segment in Thailand of approximately USD 60–80 million annually.

Q: Who is DCH Auriga?

A: DCH Auriga is an Asia-based integrated market management provider specialising in healthcare, acting as Osteopore's market authorisation holder and supply chain partner in Thailand.

Q: What ASX ticker does Osteopore trade under?

A: Osteopore Limited trades on the Australian Securities Exchange under the ticker OSX.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.